CAMBRIDGE, England & San Diego–(BUSINESS WIRE)–Abzena, the leading global biologics target to GMP partner research
organisation, announced it has appointed Dr Campbell Bunce as Chief
Scientific Officer (CSO) and Bo Adair MBA as Senior Vice President
Process and Operations.
Dr Bunce joined Abzena in November 2015 as SVP Scientific Operations and
Cambridge UK site head. The newly created CSO role recognises the strong
innovation focus and depth of scientific expertise that customers expect
from Abzena in biologic and Antibody Drug Conjugate design, discovery
and development, as well as an expectation of seamless execution. Dr
Bunce will maintain his Cambridge UK site head responsibilities in
addition to this global role.
Campbell is a twenty-year veteran of the biotechnology industry.
Throughout his career he has applied innovative solutions for the
design, manufacture and clinical evaluation of novel products including
vaccines, biologics and small molecules in multiple therapeutic areas.
These include inflammation, cancer, infectious disease and addiction.
Since joining Abzena, he has guided the expansion of its integrated
capabilities across discovery, developability, protein engineering, cell
line development, bioconjugation, analytics and bioassay services. His
education includes a PhD from the University of Manchester, an
undergraduate degree from the University of Glasgow, and numerous
scientific publications and editorials.
Dr Bunce commented: “Our customers rely on our ability to solve tough
scientific questions whilst shortening timelines and ultimately
improving clinical outcomes for patients. I view our role as developing
drugs by proxy and guide our team to partner very closely with our
customer. The combination of world class scientific excellence and
technical capabilities will maximise the likelihood of success.”
Bo Adair joins Abzena to the newly created role of Senior Vice President
Process and Operations, based in San Diego and leading project
management and process improvement globally. He is a twenty-five-year
veteran of the industry, having served in senior roles at contract
research organisations including Aptuit, and Harlan Laboratories as well
as leading management consulting organisations. He has consulted
extensively with complex organisations including Bayer, Eli Lilly,
Johnson & Johnson, Cardinal Healthcare, and the United States Army. His
background includes an MBA from the Wirtschaftsuniversität Wien &
University of South Carolina, an undergraduate degree from Auburn
University, and a qualification as a Lean Six Sigma Master Black Belt.
Bo will focus on excellence of integrated project delivery within and
across Abzena’s sites, leveraging project management, process
improvement and enabling technologies. He will ensure all processes are
optimised to ensure the highest quality standards.
Bo commented: “I am delighted to be joining the company and look forward
to working personally with Abzena’s partners to deliver their projects
on the planned timeline to the highest scientific and regulatory quality
across Abzena’s integrated design, development and GMP manufacturing
capabilities.”
Jonathan Goldman MD, CEO of Abzena, said:
“I am delighted to announce these appointments. Campbell deserves the
newly created role of CSO, which recognises his exceptional scientific
abilities and the differentiation we bring to the customer as the only
Partner Research Organization with a dedicated focus on target to GMP
for biologics and ADCs. Our customers expect more than just CMO
services. Separately, I had the privilege of working with Bo Adair for
many years and am extremely pleased that we have an executive of his
calibre to allow us to scale up our integrated solutions operation as
demand and the number of projects grow. Our focus is making a difference
for patients and I am confident that Campbell and Bo will help achieve
that goal.”
About Abzena
Abzena provides the most complete set of solutions in integrated early
discovery to mid-phase biotherapeutic and ADC drug development services
in the pharmaceutical industry. The company maintains resources around
the world, with facilities in the US and UK. Abzena is partnered with
Welsh, Carson, Anderson & Stowe, one of the world’s leading private
equity investors. For more information, please see www.abzena.com.
Contacts
Abzena
Joseph Reeds
joseph.reeds@abzena.com
+44
1223 903367